Selected research
Industry Research
Solid Dosage Form Drug Industry Research Report 2026
Market perspective
The global Solid Dosage Form Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Solid Dosage Form Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Solid Dosage Form Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Solid Dosage Form Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Solid Dosage Form Drug include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly & Co., Pfizer and GlaxoSmithKline, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Solid Dosage Form Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Solid Dosage Form Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Solid Dosage Form Drug Market by Company
Takeda
Teva
Sanofi
Johnson & Johnson
Novartis
Roche
Eli Lilly & Co.
Pfizer
GlaxoSmithKline
Biogen
Bayer
Bristol Myers Squibb
Amgen
AbbVie
AstraZeneca
Merck & Co.
Gilead Sciences
Boehringer Ingelheim
Astellas
Solid Dosage Form Drug Segment by Type
Tablet
Capsules
Other
Solid Dosage Form Drug Segment by Application
Hospital
Retail Pharmacy
Other
Solid Dosage Form Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Dosage Form Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Solid Dosage Form Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Dosage Form Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Solid Dosage Form Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Capsules
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Takeda
- Teva
- Sanofi
- Johnson & Johnson
- Novartis
- Roche
- Eli Lilly & Co.
- Pfizer
- GlaxoSmithKline
- Biogen
- Bayer
- Bristol Myers Squibb
- Amgen
- AbbVie
- AstraZeneca
- Merck & Co.
- Gilead Sciences
- Boehringer Ingelheim
- Astellas
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Solid Dosage Form Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tablet
- 2.2.3 Capsules
- 2.2.4 Other
- 2.3 Solid Dosage Form Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Solid Dosage Form Drug Breakdown Data by Type
- 3.1 Global Solid Dosage Form Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Solid Dosage Form Drug Forecasted Market Size by Type (2027-2032)
4 Solid Dosage Form Drug Breakdown Data by Application
- 4.1 Global Solid Dosage Form Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Solid Dosage Form Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Solid Dosage Form Drug Market Perspective (2021-2032)
- 5.2 Global Solid Dosage Form Drug Growth Trends by Region
- 5.2.1 Global Solid Dosage Form Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Solid Dosage Form Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Solid Dosage Form Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Solid Dosage Form Drug Market Dynamics
- 5.3.1 Solid Dosage Form Drug Industry Trends
- 5.3.2 Solid Dosage Form Drug Market Drivers
- 5.3.3 Solid Dosage Form Drug Market Challenges
- 5.3.4 Solid Dosage Form Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Solid Dosage Form Drug Players by Revenue
- 6.1.1 Global Top Solid Dosage Form Drug Players by Revenue (2021-2026)
- 6.1.2 Global Solid Dosage Form Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Solid Dosage Form Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Solid Dosage Form Drug Head Office and Area Served
- 6.4 Global Solid Dosage Form Drug Players, Product Type & Application
- 6.5 Global Solid Dosage Form Drug Manufacturers Established Date
- 6.6 Global Solid Dosage Form Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Solid Dosage Form Drug Market Size (2021-2032)
- 7.2 North America Solid Dosage Form Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Solid Dosage Form Drug Market Size by Country (2021-2026)
- 7.4 North America Solid Dosage Form Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Solid Dosage Form Drug Market Size (2021-2032)
- 8.2 Europe Solid Dosage Form Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Solid Dosage Form Drug Market Size by Country (2021-2026)
- 8.4 Europe Solid Dosage Form Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Solid Dosage Form Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Solid Dosage Form Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Solid Dosage Form Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Solid Dosage Form Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Solid Dosage Form Drug Market Size (2021-2032)
- 10.2 South America Solid Dosage Form Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Solid Dosage Form Drug Market Size by Country (2021-2026)
- 10.4 South America Solid Dosage Form Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Solid Dosage Form Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Solid Dosage Form Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Solid Dosage Form Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Solid Dosage Form Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.1.4 Takeda Solid Dosage Form Drug Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.2.4 Teva Solid Dosage Form Drug Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.3.4 Sanofi Solid Dosage Form Drug Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Johnson & Johnson
- 12.4.1 Johnson & Johnson Company Information
- 12.4.2 Johnson & Johnson Business Overview
- 12.4.3 Johnson & Johnson Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.4.4 Johnson & Johnson Solid Dosage Form Drug Product Portfolio
- 12.4.5 Johnson & Johnson Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.5.4 Novartis Solid Dosage Form Drug Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.6.4 Roche Solid Dosage Form Drug Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Eli Lilly & Co.
- 12.7.1 Eli Lilly & Co. Company Information
- 12.7.2 Eli Lilly & Co. Business Overview
- 12.7.3 Eli Lilly & Co. Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.7.4 Eli Lilly & Co. Solid Dosage Form Drug Product Portfolio
- 12.7.5 Eli Lilly & Co. Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.8.4 Pfizer Solid Dosage Form Drug Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 GlaxoSmithKline
- 12.9.1 GlaxoSmithKline Company Information
- 12.9.2 GlaxoSmithKline Business Overview
- 12.9.3 GlaxoSmithKline Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.9.4 GlaxoSmithKline Solid Dosage Form Drug Product Portfolio
- 12.9.5 GlaxoSmithKline Recent Developments
- 12.10 Biogen
- 12.10.1 Biogen Company Information
- 12.10.2 Biogen Business Overview
- 12.10.3 Biogen Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.10.4 Biogen Solid Dosage Form Drug Product Portfolio
- 12.10.5 Biogen Recent Developments
- 12.11 Bayer
- 12.11.1 Bayer Company Information
- 12.11.2 Bayer Business Overview
- 12.11.3 Bayer Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.11.4 Bayer Solid Dosage Form Drug Product Portfolio
- 12.11.5 Bayer Recent Developments
- 12.12 Bristol Myers Squibb
- 12.12.1 Bristol Myers Squibb Company Information
- 12.12.2 Bristol Myers Squibb Business Overview
- 12.12.3 Bristol Myers Squibb Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.12.4 Bristol Myers Squibb Solid Dosage Form Drug Product Portfolio
- 12.12.5 Bristol Myers Squibb Recent Developments
- 12.13 Amgen
- 12.13.1 Amgen Company Information
- 12.13.2 Amgen Business Overview
- 12.13.3 Amgen Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.13.4 Amgen Solid Dosage Form Drug Product Portfolio
- 12.13.5 Amgen Recent Developments
- 12.14 AbbVie
- 12.14.1 AbbVie Company Information
- 12.14.2 AbbVie Business Overview
- 12.14.3 AbbVie Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.14.4 AbbVie Solid Dosage Form Drug Product Portfolio
- 12.14.5 AbbVie Recent Developments
- 12.15 AstraZeneca
- 12.15.1 AstraZeneca Company Information
- 12.15.2 AstraZeneca Business Overview
- 12.15.3 AstraZeneca Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.15.4 AstraZeneca Solid Dosage Form Drug Product Portfolio
- 12.15.5 AstraZeneca Recent Developments
- 12.16 Merck & Co.
- 12.16.1 Merck & Co. Company Information
- 12.16.2 Merck & Co. Business Overview
- 12.16.3 Merck & Co. Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.16.4 Merck & Co. Solid Dosage Form Drug Product Portfolio
- 12.16.5 Merck & Co. Recent Developments
- 12.17 Gilead Sciences
- 12.17.1 Gilead Sciences Company Information
- 12.17.2 Gilead Sciences Business Overview
- 12.17.3 Gilead Sciences Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.17.4 Gilead Sciences Solid Dosage Form Drug Product Portfolio
- 12.17.5 Gilead Sciences Recent Developments
- 12.18 Boehringer Ingelheim
- 12.18.1 Boehringer Ingelheim Company Information
- 12.18.2 Boehringer Ingelheim Business Overview
- 12.18.3 Boehringer Ingelheim Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.18.4 Boehringer Ingelheim Solid Dosage Form Drug Product Portfolio
- 12.18.5 Boehringer Ingelheim Recent Developments
- 12.19 Astellas
- 12.19.1 Astellas Company Information
- 12.19.2 Astellas Business Overview
- 12.19.3 Astellas Revenue in Solid Dosage Form Drug Business (2021-2026)
- 12.19.4 Astellas Solid Dosage Form Drug Product Portfolio
- 12.19.5 Astellas Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst